science

List of investigational attention deficit hyperactivity disorder drugs

List of investigational attention deficit hyperactivity disorder drugs is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand List of investigational attention deficit hyperactivity disorder drugs rather than just read about it. In short: This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

Key takeaways

List of investigational attention deficit hyperactivity disorder drugs belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect List of investigational attention deficit hyperactivity disorder drugs to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of List of investigational attention deficit hyperactivity disorder drugs from memory before moving on to harder problems.

Reference excerpt

This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in September 2021. It is likely to become outdated with time.

Under development

Preregistration ATT-377 – combination treatment of methylphenidate extended-release and cyproheptadine TRN-110 [extended-release] – undefined mechanism / extended-release form of an undisclosed drug

Phase 3 clinical trials Dexmethylphenidate [controlled release] (CTX-1301) – norepinephrine–dopamine reuptake inhibitor Edivoxetine (LY-2216684) – norepinephrine reuptake inhibitor Molindone [extended-release] (AFX-2201, EN-1733A, molindone XR, SPN-810, SPN-810M, Zalvari) – antipsychotic / dopamine D2 receptor antagonist and serotonin 5-HT2B receptor antagonist — specifically under development for impulsive aggression in ADHD Serdexmethylphenidate (KP-484) – dexmethylphenidate prodrug / norepinephrine–dopamine reuptake inhibitor Solriamfetol (ADX-N05, ARL-N05, JZP-110, SKL-N05; Sunosi) – norepinephrine–dopamine reuptake inhibitor

Phase 2 clinical trials CX-717 – ampakine / AMPA receptor modulator Mazindol [controlled release] (NLS-0, NLS-1, NLS-10, NLS-13, NLS-2, Nolazol, Quilience) – serotonin–norepinephrine–dopamine reuptake inhibitor PDC-1421 (BLI-1005) – norepinephrine reuptake inhibitor

Phase 1 clinical trials AFX-2401 – "neurotransmitter modulator" Atomoxetine [oral solution] (TAH-9922) – norepinephrine reuptake inhibitor Dextroamphetamine [abuse-deterrent immediate-release] (ADAIR) – norepinephrine–dopamine releasing agent

Preclinical/research Atomoxetine [oral suspension] – norepinephrine reuptake inhibitor Dextroamphetamine [controlled release] (CTX-1302) – norepinephrine–dopamine releasing agent NNI-351 – DYRK1A inhibitor and "neurogenesis enhancer"

No development reported AFI-002 – undefined mechanism Altropane (123-I Altropane®, [123I]-E-IACFT Injection, [123I]NAV5001, CFT, Iodine-123-E-IACFT Injection, NAV-5001, O-587) – dopamine reuptake inhibitor / single-photon emission-computed tomography enhancer Amphetamine [oral abuse-deterrent immediate-release] (ADAIR) – norepinephrine–dopamine releasing agent Bavisant (BEN-2001, JNJ-1074, JNJ-31001074) – histamine H3 receptor antagonist BCWP-E003 – undefined mechanism BLI-1008 – undefined mechanism Brilaroxazine (RP-5000, RP-5063) – atypical antipsychotic / dopamine receptor partial agonist and serotonin receptor modulator Cannabidiol/gabapentin (Cannbleph) – cannabinoid receptor modulator and gabapentinoid Ciforadenant (CPI-444, V-81444) – adenosine A2A receptor antagonist CM-4612 (CM-ADHD, CM-AT, CM-PK) – gastrointestinal/pancreatic enzyme replacement therapy CRD-102 – undefined mechanism Dasotraline (DSP-225289, SEP-225289, SEP-0225289, SEP-225289-HCI, SEP-289) – serotonin–norepinephrine–dopamine reuptake inhibitor Dextroamphetamine [abuse-resistant] (PF-08, PFR 08001, PFR08026) – norepinephrine–dopamine releasing agent Dextroamphetamine sulfate [modified release capsules] (HLD-900, HLD-100) – norepinephrine–dopamine releasing agent Dopamine [intranasal] (DopaMat, MPP-18) – dopamine receptor agonist Eltoprazine (DU-28853) – serotonin 5-HT1A and 5-HT1B receptor agonist Fasoracetam [co-crystallised] (AEVI-004, NFC-1) – racetam / metabotropic glutamate receptor modulator GTS-21 (DMXB-A, DMXB-A sustained release, DMXB-A-SR) – α7 nicotinic acetylcholine receptor agonist Guanfacine [once-daily] (Guanfacine Carrier Wave, SPD-547) – α2-adrenergic receptor agonist IPX-233 (IPX233 ER C0003, IPX233-C0001, IPX233-C0002, IPX233-T0001, IPX233-T0002) – central nervous system stimulant Masupirdine (M1, M1 of SUVN-502, SUVN-502, SVN-502) – serotonin 5-HT6 receptor antagonist Methylphenidate [extended-release/abuse-resistant] (COL-171) – norepinephrine–dopamine reuptake inhibitor Methylphenidate [fast dissolve tablet] [Samyang Holdings Biopharmaceuticals] – norepinephrine–dopamine reuptake inhibitor Methylphenidate [transdermal system] (SHX-009) – norepinephrine–dopamine reuptake inhibitor Methylphenidate/naltrexone (AVK-001) – norepinephrine–dopamine reuptake inhibitor and opioid receptor antagonist Nic-12 – undefined mechanism NLS-2 – antianaemic / heavy metal / iron replacement PD-3044 – dopamine reuptake inhibitor Pitolisant (tiprolisant; BF-2.649, BF-2649, Ozawade, Wakix) – histamine H3 receptor antagonist R-Sibutramine metabolite ((+)-desmethylsibutramine, (+)-didesmethylsibutramine, R-DDMS, R-desmethylsibutramine, R-didesmethylsibutramine) – serotonin–norepinephrine–dopamine reuptake inhibitor Selegiline [transdermal] (Emsam) – monoamine oxidase B inhibitor SKL-13865 (SKL-ADHD) – norepinephrine–dopamine reuptake inhibitor Sofinicline (A-422894.0, ABT-894) – α4β2 nicotinic acetylcholine receptor modulator SPN-811 – undefined mechanism Taminadenant (NIR-178, PBF-509) – adenosine A2A receptor antagonist

Research programmes Ampakines / AMPA receptor modulators [RespireRx] (CX-516, CX-614, CX-707, CX-929, CX-1501, CX-1763, CX-1796, CX-1837, CX-1846, CX-1942, CX-2007, CX-2076) Cannabis extracts [Cannabis Science] (CBIS GAP-001, CBIS LC-001, CBIS OBLD-001, CBIS OCD-001, CBIS PC-001, CBIS PPC-001, CBIS PS-001, CBIS SD-001, CBIS SSA-001, CBIS-OS-001, CBIS-PTSD-001, CS NEURO 1, CS-S/BCC-1, CS-TATI-1) – cannabinoid receptor modulators Norepinephrine reuptake inhibitors / adrenergic receptor antagonists [Pfizer] (NRI-022, NRI-193, WAY-253203, WAY-256805, WAY-260022, WAY-315193, WAY-318068) Pim2 / PolyPhetamine [ITL Pharma] Subtype-selective glutamate NMDA receptor modulators / glutamate NR2B receptor modulators [Novartis]

Not under development

… excerpt ends here. Continue reading the full article.

Worked examples

Example 1 — a first encounter with List of investigational attention deficit hyperactivity disorder drugs

Start with the simplest possible case. Write down what List of investigational attention deficit hyperactivity disorder drugs claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to List of investigational attention deficit hyperactivity disorder drugs before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about List of investigational attention deficit hyperactivity disorder drugs ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of List of investigational attention deficit hyperactivity disorder drugs

In research: List of investigational attention deficit hyperactivity disorder drugs appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses List of investigational attention deficit hyperactivity disorder drugs in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: List of investigational attention deficit hyperactivity disorder drugs is common in secondary-school and first-year university syllabi. It links to neighbouring topics Attention deficit hyperactivity disorder, Experimental psychiatric drugs, Lists of investigational drugs, so understanding it makes those chapters shorter.
In everyday life: Look for List of investigational attention deficit hyperactivity disorder drugs outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “List of investigational attention deficit hyperactivity disorder drugs” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study List of investigational attention deficit hyperactivity disorder drugs in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what List of investigational attention deficit hyperactivity disorder drugs means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain List of investigational attention deficit hyperactivity disorder drugs out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is List of investigational attention deficit hyperactivity disorder drugs in simple terms?

Why does List of investigational attention deficit hyperactivity disorder drugs matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study List of investigational attention deficit hyperactivity disorder drugs?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on List of investigational attention deficit hyperactivity disorder drugs.